Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Chondroitin sulfate - Bioiberica

Drug Profile

Chondroitin sulfate - Bioiberica

Alternative Names: Chondroitin sulfate CS b-Bioactive®; Chondroitin sulphate - Bioiberica; Condro-Sorb; Condrosan; Condrosulf (Bioiberica)

Latest Information Update: 30 Apr 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bioiberica
  • Class Anti-inflammatories; Antirheumatics; Glycosaminoglycans
  • Mechanism of Action Collagen stimulants; Leucocyte elastase inhibitors; Proteoglycan stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Musculoskeletal disorders; Osteoarthritis; Rheumatic disorders

Most Recent Events

  • 24 Apr 2018 Registered for Osteoarthritis (Combination therapy) in Finland, Poland, Hungary, Austria, France (PO) through mutual recognition process from Spain
  • 24 Apr 2018 Registered for Osteoarthritis (Combination therapy) in Spain (PO)
  • 24 Apr 2018 Bioiberica plans to launch the combination drug of chondroitin sulphate and glucosamine hydrochloride by 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top